Reuters

UCB's Cimzia could be cheaper than rival drugs

BARCELONA, June 14 (Reuters) - UCB SA's experimental arthritis treatment Cimzia could be priced at a discount to rivals, since the drug has lower production costs, a key scientific investigator on the ...
Nasdaq

CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis

According to the updated label, the recommended dose of CIMZIA for adult patients with nr-axSpA is 400 mg (given as 2 subcutaneous injections of 200 mg each) initially and at weeks 2 and 4, followed ...
FierceBiotech

UCB's CIMZIA® (certolizumab pegol) approved by the U.S. FDA for adult patients suffering from moderate to severe rheumatoid art

UCB's CIMZIA® (certolizumab pegol) approved by the U.S. FDA for adult patients suffering from moderate to severe rheumatoid arthritis Available this week, Cimzia® (certolizumab pegol), the only ...
Monthly Prescribing Reference

FDA Approves First Treatment for Non-Radiographic Axial Spondyloarthritis

The FDA has approved Cimzia (certolizumab pegol; UCB) injection for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, the first ...
ABC News

Cimzia Approved for Rheumatoid Arthritis

May 15 -- THURSDAY, May 14 (HealthDay News) -- The U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) to treat moderate-to-severe rheumatoid arthritis, Belgian drug maker UCB ...